Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Sitagliptin/Metformin ER Tablets in Healthy Subjects
NCT07763912Phase 1Completed
- Sponsor
- Adium Pharma
- Start
- Nov 2025
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sitagliptin and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Adium Pharma. Primary endpoints: Maximum Observed Plasma Concentration at 72 hours and Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration at 72 hours. Started Nov 2025; status: completed.
02
Drugs
sitagliptinliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07763912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07763912.